Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib, uhCG/EGF, and Corticosteroids for High-Risk aGVHD
NCT05123040Phase 2Terminated
- Sponsor
- Masonic Cancer Center
- Start
- Jun 2023
- Primary completion
- Feb 2026
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ruxolitinib, human chorionic gonadotropin, corticosteroids in Acute Graft-Versus-Host Disease (aGvHD), sponsored by Masonic Cancer Center. Started Jun 2023; status: terminated.
02
Drugs
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT05123040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05123040.